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Abstract
Malaria still  remains one of the highest childhood killer diseases, especially in the
developing countries of Africa, Southeast Asia, and Eastern Mediterranean regions.
With an estimated 100 million cases and 300,000 deaths from malaria annually, Nigeria
has one of the highest burdens of malaria in the world, with children mostly affected.
It accounts for 60% of outpatient visits, 30% hospitalization among children under 5
years of age. Great efforts and huge funding have been committed globally towards the
fight for malaria, but malaria continues to be a major challenge in these developing
countries, especially countries in Sub-Saharan Africa. The World Health Organisation
adopted  a  cost-effective  intervention  strategy,  which  comprises  a  three-pronged
approach: vector control, chemoprophylaxis, and case management. Case management
involves early diagnosis and treatment. This chapter looks at the challenges militating
against the achievement of this important aspect of malaria control in children as well
as efforts that have been made or not made to overcome these challenges using Nigeria
as a case study.
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1. Introduction
Malaria still remains one of the highest childhood killer diseases, especially in the developing
countries  of  Africa,  Southeast  Asia,  and  Eastern  Mediterranean  regions.  In  Africa,  it  is
estimated that malaria kills one child every 2 minutes [1]. According to the latest estimates
from the World Health Organisation (WHO), there were 214 million new cases of malaria
worldwide in 2015 with an estimated 438 000 malaria deaths [1]. Most of these cases (88%)
and deaths (90%) were recorded in the African region [1]. Nigeria and the Democratic Republic
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of Congo, both in African region, accounted for about 40% of the total estimated malaria deaths
worldwide. The Southeast Asia and the Eastern Mediterranean regions account for the few
remaining cases in that order. The denominator in all these regions, apart from the favourable
weather conditions for the breeding of malaria parasite-carrying mosquitoes, is the wide-
spread poverty and systemic inadequacies: lack of political will and poor health systems in
many of the countries that make up the regions. In parts of the world where malaria is endemic,
severe malaria is mainly a disease of children under the age of 5 years due to the acquisition
of specific immunity against plasmodium; the malaria-causing parasite as the child gets older,
providing some protection (though incomplete) against malaria [2]. Malaria is endemic in
most countries of Sub-Saharan Africa with the children and pregnant women population
being the most vulnerable to the disease. Of the estimated 438,000 malaria deaths worldwide,
children under the age of 5 years constitute 306,000 (70%) [1].
Despite these seemingly very high figures, there has been marked decline in the mortality from
malaria. The global cases of malaria declined by 18% from an estimated 262 million in the year
2000 to 214 million in 2015. The death rate decreased by 48% from a global estimate of 839,000
in year 2000 to 438,000 in 2015. In children under the age of 5 years, the number of malaria
deaths fell from an estimated 723,000 in year2000 to 306,000 in 2015, a decrease of about 58%
(Table 1). This has come through the combined efforts of the World Health Organisation, its
Rollback Malaria Partners and the various governments in the different countries afflicted by
the malaria scourge.
WHO region Estimated malaria deaths by year Percentage reduction
2000 2005 2010 2015 2000–2015
Africa 694,000 5910,000 410,000 292,000 −58%
Americas 400 300 300 100 −66%
Eastern Mediterranean 5300 5200 2000 2200 −58%
European 0 0 0 0 0
Southeast Asia 19,000 16,000 14,000 10,000 −49%
Western Pacific 4,700 2,000 1,600 1,500 −68%
World 723,000 614,000 428,000 306,000 −58%
Source: World Malaria Report 2015.
Table 1. Estimated number of malaria deaths in children under the age of 5 years from year 2000 to 2015 by the WHO
region.
To achieve this, the WHO adopted a cost-effective intervention strategy, which comprises a
three-pronged approach: vector control, chemoprophylaxis, and case management. The vector
control involves the prevention of mosquitoes from acquiring or transmitting infection through
the use of long lasting insecticidal nets (LLIN) and indoor residual spray (IRS). Chemopro-
phylaxis involves the use of antimalarial drugs to suppress and prevent the establishment of
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infection in the human, whereas case management involves the prompt diagnosis and
treatment of malaria.
Although these strategies are said to be cost effective, the achievements recorded in the fight
against malaria has not come at a cheap price. The global cost of fighting malaria increased
from the sum of US$ 960 million in year 2000 to a whopping US$ 2.5 billion in 2014 [1]. The
majority of these funds were contributed by international partners (donor agencies). In spite
of these global efforts and huge funding for malaria control, malaria continues to be a major
challenge in these developing countries, especially countries in Sub-Saharan Africa. These
challenges in the fight against malaria, with particular attention to case management, are
discussed below using Nigeria as a case study.
2. Nigeria and malaria burden
As the most populous country in Africa, Nigeria contributes the majority of the Africa malaria
burden. The country has an estimated total population of approximately 172 million (2014
estimate) with an annual growth rate of about 2.7% and a GDP per capita of US$1091.64 (2014)
and inflation rate of 9.0% (2015) [3]. The public health sector in Nigeria is run by the three tiers
of government: federal, state, and local governments. The federal government co-ordinates the
affairs of the tertiary health facilities and provides overall policy and technical support to the
health sector. The state government co-ordinates those of the secondary centres and some state-
owned tertiary centres and also lend support to the primary health sector. The local govern-
ment takes care of the primary health centres, which have gone moribund in many parts of
the country. The annual health budget is usually well below 10% of the total budget. For
instance; in 2015, it was 6.3%, whereas in 2016, it dropped to about 3.7%. In general, the
country’s health system may be described as weak due to inadequate funding and supervision.
Nigeria, being a tropical country, has one of the best combinations of adequate rainfall,
temperature, and humidity, allowing for the breeding and survival of the female anopheline
mosquitoes, the malaria vector. Most (97%) of the malaria in Nigeria are mainly due to
Plasmodium falciparum, with Plasmodium ovale and Plasmodium malariae affecting only a few
persons. Although, severe malaria is mostly caused by P. falciparum, Plasmodium vivax,and
Plasmodium knowlesi have also been indicated in causing severe disease [2]. However, P. vivax
does not occur in indigenous Nigerians [4], and there is no documentation of P. knowlesi in any
Nigeria.
Malaria remains a major public health problem in Nigeria. It accounts for more cases and
deaths than in any other country in the world. There are an estimated 100 million malaria cases
with over 300,000 deaths per year in Nigeria [5]. Malaria accounts for 60% of outpatient visits
and 30% of hospitalizations among children under 5 years of age in Nigeria [5]. This implies
a huge loss in terms of financial resources and man hours and in the case of the school age
child, loss of school hours [6–8].
In line with the World Health Organization recommendation, the country has adopted the
Test, Treat, and Track (3T) strategy with all suspected cases of malaria properly diagnosed
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using Rapid Diagnostic Tests or microscopy, treated promptly with recommended artemisinin-
based combination therapy (ACT) if the result is positive and documented [4].
3. Malaria diagnosis
3.1. Clinical diagnosis
WHO has identified early diagnosis as the first step in the treatment of malaria. This is
necessary to prevent progression of the disease to severe forms. Malaria does not have any
specific symptoms and signs and as such may mimic several tropical childhood illnesses [9].
These include bacterial sepsis, enteric fever, pneumonia, meningitis, urinary tract infection,
otitis media, and pharyngitis. This makes the specificity of clinical diagnosis of malaria very
poor and thus gives room for indiscriminate use of antimalarials especially in endemic areas.
In some cases, malaria may co-exist with any of these other conditions [10–13], necessitating
more competent health personnel in the management. Studies [14–16] have shown that
treatment based on clinical information alone leads to over diagnosis and over treatment of
malaria. In addition, there may be increased morbidity and possible death from the neglected
disease causing the child’s symptoms.
Even with the unreliability and consequences of reliance on clinical information alone for
malaria diagnosis, a large proportion of healthcare providers in Nigeria still treat malaria
presumptively [14, 17, 18]. The 2013 Nigeria Demographic and Health Survey indicated that
the average rate of antigen or parasite detection in children before treatment was 11.1% [19].
Reasons adduced for the presumptive diagnosis by the healthcare providers included delay
in getting a blood microscopy from hospital laboratories, unavailability of malaria rapid
diagnostic test (mRDT), reliance on blood tests create an impression of incompetence of the
health personnel, as well as malaria being the first suspect in any child with fever since malaria
is endemic in Nigeria [17]. According to WHO, less than half of the suspected malaria cases in
most malaria endemic regions are truly infected with malaria parasite, hence their insistence
on laboratory confirmation before treatment [1].
3.2. Parasite detection
In line with the WHO policy, the national malaria guideline of Nigeria recommends the
confirmation of all suspected cases of malaria by parasitological testing either with microscopy
or by the use of mRDT. This is particularly important as accurate diagnosis before treatment
will enhance a more targeted therapy, reduce the duration of illness, and may even prevent
death from treatment of another disease as malaria. It will help prevent drug resistance and
also enhance the diagnosis and case management of other diseases that may mimic malaria in
children since the exclusion of malaria will mean a search for the cause of illness. Apart from
saving lives, both money and man hours are saved.
The challenge with this confirmation test is mainly that of availability and willingness to go for
test before treatment. Microscopy, which still remains the gold standard, is fast disappearing
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from many health facilities. The reasons range from inability to acquire new or replace old and
damaged microscopes to absence of a qualified microscopist. In addition, ready availability of
reagents and slides for use with the microscopes, where available may be a problem. There is
also the need for quality assurance, which is virtually non-existence in most health facilities in
the country. Another important consideration is the need for electrical power, which is a big
issue in the country. The alternative is the mRDT, which is an antigen detection test. Three
antigens: Plasmodium falciparum histidine-rich protein 2 (PfHRP2), plasmodial aldolase, and
plasmodial lactate dehydrogenase (pLDH) are currently used for mRDTs. The pfHRP2 mRDTs
are the most commonly available types in Nigeria and seem most suited for the country as up
to 97% of the malaria cases are due to P. falciparum. The test is easier to conduct and requires
neither power supply nor any expertise. It is usually available as a pre-packed ready-to-use kit
with a single container of buffer solution in every box of kits. Since the adoption of the mRDT
by the WHO, the number of the products has continued to increase rapidly with over 200
different products available in the market worldwide [20]. This rapid proliferation of brands
also lead to increase in the number of substandard products, which easily find their way into
developing countries like Nigeria with less stringent quality control. Reviews and studies show
that the commercially available MRDTs show wide variability in diagnostic sensitivity and
specificity [21–25]. To stem this “influx,” WHO has continued to conduct testing of the products
and issuing guidelines to assist countries adopt the mRDT for use [20].
Since the introduction of RDT kits, there has been increased knowledge of mRDT by healthcare
givers and increasing availability at health facilities, but its regular utilization to confirm
suspected cases of malaria by these health workers prior to treatment is not encouraging [17,
26]. Another major concern is the fact that a good number of these mRDTs have high false
negative results at lower antigen titre (200–500 parasites/ml) [20, 23]. For the detection of P.
falciparum in all transmission settings, WHO recommended the panel detection score against
P. falciparum samples should be at least 75% at 200 parasites/μL [27]. The Nigerian malaria
treatment guideline recommends the use of an alternate diagnostic test where continued
suspicion exists after a negative test [4]. Some authors have recommended the combined use
of two methods to confirm the diagnosis of malaria [22]. This invariably adds to the cost of
treatment as well as time spent at the health facility, which many healthcare givers and patients
will evade. Also, quality and performance check of the mRDTs is partly absent or non-existent
in malaria-endemic countries, including Nigeria [20]. The quality of the mRDT may be affected
the very high temperatures (above 40°C) such as can be found in some parts of the country. It
is important to note that although mRDT may constitute an extra cost to the case management
of malaria, it is no doubt a cost-effective innovation, even more cost effective than microscopy
[28]. Despite these challenges with the use of mRDT and microscopy, they are still very useful
components of malaria case management.
4. Malaria treatment
In consonance with the WHO recommendation on the treatment of malaria, the Nigerian
government adopted the use of artemether-lumefantrine (AL) for the treatment of uncompli-
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cated malaria and artesunate-amodiaquine (AA) as alternative [4]. For severe falciparum malaria
treatment, the drug of choice is intravenous artesunate with parenteral artemether or quinine as
alternatives where intravenous artesunate is not available. For settings where a complete
treatment of severe malaria is not feasible, a pre-referral treatment with intramuscular or rectal
artesunate or intramuscular quinine in this order of preference is recommended.
Although the Nigerian government had adopted AL and AA as the first and second line
respectively, several brands of other ACTs are widely available and used in the country. These
include artesunate-mefloquine, dihydroartemisinin-piperaquine, artemisinin-piperaquine,
and artesunate-sulfadoxine pyrimethamine. Regardless of the constellation of ACT antima-
larial drugs available, many children still receive monotherapy notably chloroquine and
sulfadoxine-pyrimethamine especially among the lower socioeconomic class and those with
uneducated or under educated parents [17, 29]. Other commonly used antimalarial mono-
therapy in children include oral artesunate, amodiaquine, halofantrine, and oral quinine and
paludrine [29, 30]. The drawback in this practice is the progression to severe malaria with its
consequences, which include prolonged hospitalization, increased cost of treatment, avoidable
blood transfusions, and even death. The frequent prescription of concomitant medications in
the form of different antipyretics, sometimes multiple, haematinics, multivitamin prepara-
tions, and antibiotics, which are mostly inappropriate also add to the cost of treatment and
burden of medications for the child [29]. In Sub-Saharan Africa, the proportion of children
aged under 5 years, who received an ACT, is estimated to have increased from less than 1% in
2005 to 16% in 2014, but still falls substantially short of the target of universal access for malaria
case management [1]. One important reason for this poor situation is that a greater proportion
of children with fever are treated outside the health sector.
In Nigeria, only about 35% of children receive treatment at government health facilities [19].
The rest are treated by the patent medicine vendors (PMV), pharmacy shops, private health
facilities, or by traditional medicine practitioners. In the light of this, the government of Nigeria
with the assistance of Roll back Malaria partners and donor agencies tried to scale up the
treatment of malaria through the engagement of the private sectors, especially the PMVs whom
they have trained in some states of the federation and the provision of pre-packaged, age-
specific antimalarials for easier dosing [19]. A study by Berendes et al. [31] in the northern part
of Nigeria showed that patent medicine vendors are not reliable in the treatment of malaria
because most PMVs were ignorant of and lacked training about new treatment guidelines that
had endorsed ACTs as first-line treatment for uncomplicated malaria. They stocked and
dispensed monotherapy to patients with suspected malaria. However, another study [32] in
the southern part of the country showed an improved knowledge of ACT by PMVs, but yet
other non-recommended antimalarial drugs such as chloroquine were still sold to customers
without prescription. Another worrisome trend is the prevalent use of various forms of herbal
medications in the treatment of malaria even in urban areas [7, 33, 34]. Some of these herbal
preparations, which mostly do not have standard dosage, have the potential to cause liver or
kidney damage [35].
The cost of malaria treatment is also a contributing factor to the non-use of ACT because this
remains high for the average Nigerian. In 2009, the cost of treating a child was about US$6.58,
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which was mostly on out of pocket expenses [8]. Although a national health insurance scheme
is available, only a very small percentage of the population, mainly federal civil servants and
staff of big companies, have access to it.
Another major challenge with the treatment of malaria in Nigerian children is the high rate of
fake and substandard antimalarial drugs [36, 37]. This brought about a lot of confusion to the
healthcare provider regarding the possibility of co-morbidities when the child failed to
respond to the proper treatment. This may lead to the administration of unwarranted antibi-
otics while the child deteriorates from untreated malaria. However, the situation has improved
significantly in recent times [36]. The rate of fake and substandard drugs in the country
improved from about 41% in 2002 to about 10% in 2010 [36]. The fight is still ongoing by the
country’s National Agency for Food and Drug Administration and Control (NAFDAC) to
eradicate fake drugs from the country.
5. Other challenges
5.1. Co-morbidity with chronic diseases
Nigeria being a developing country has its fair share of children with chronic diseases, such
as malnutrition, HIV/AIDS, and sickle cell anaemia. These children equally suffer from
malaria, which is usually more severe than in the normal child [38–40]. Managing such children
could pose a great challenge. Apart from the complications such as severe anaemia, which are
more prevalent in these children [38–40], concurrent management of the underlying disease
in the face of challenging finances often result in difficult decisions.
5.2. Blood transfusion
Children with severe malaria anaemia suffer greatly due to the difficulty in obtaining safe
blood for transfusion. The primary health facilities and many private facilities do not have
logistics to store blood. Patients requiring blood transfusions in these facilities are either
referred to tertiary centres or made to purchase blood from private blood banks at very
exorbitant prizes, some of which the safety are not guaranteed. In some cases, the child may
be unable to make it alive to the referred centre. Those who do often face many logistic
challenges ranging from cost of processing to provision of donor to replace the transfused
blood.
5.3. Delayed presentation
Late presentation usually results in delay in initiation of the right and adequate treatment. No
doubt this contributes significantly to the malaria mortality in children. Factors responsible
may include poverty, inadequate home treatment, and lack of access to standard treatment
centres. Certain traditional beliefs such as association of fever with teething and growth may
also delay presentation. Likewise, the increasing belief in unorthodox treatment such as herbal
medications and faith-based healing may also lead to delays in presentation.
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5.4. Geographic inequality of health facilities and personnel
Although majority of Nigerians reside in the rural areas, only a small proportion of health
facilities are located there and these are mainly primary and secondary care facilities. Likewise,
fewer personnel are available in these rural communities. As a result, most patients with severe
forms of malaria will need to travel some distance with all the attendant challenges such as
bad roads.
6. Conclusion
Despite all these numerous challenges plaguing the management of malaria in Nigerian
children, there have been significant gains in the fight against malaria as evidenced by the
improved indices. Thanks to all the Rollback Malaria partners operating in the country.
However, a lot of commitment and willingness to translate what is on paper to action is still
expected from the Nigerian government.
First is to strengthen the health systems at all levels from primary to tertiary in order to restore
the hopes of the numerous Nigerians who die because they cannot afford standard private
health facility treatments. This should include the recruitment and adequate training and
retraining of healthcare personnel in all the primary and secondary care centres to be able to
make proper diagnosis and treat malaria cases. Also, adequate equipping of all the government
health facilities with diagnostic facilities and eradication of the “out of stock syndrome” for
antimalarial drugs.
There should be strengthening of the already on-going awareness creation through the media
to sensitize the public on the need to seek care early and at government approved health
facilities.
There should be continuous appraisal of the antimalarial drugs and mRDTs in the country
with a view of identifying and expunging the substandard and fake ones. The large number
of different brands of ACTs and in the country need to be pruned down to just a few quality
and trusted brands.
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